Dermoscopic evaluation of efficacy of 308 nm Excimer Laser in treatment of alopecia areata: A prospective study
DOI:
https://doi.org/10.66344/jpad.v34i4.2737Keywords:
Alopecia areata, Excimer laser, Dermoscopy, Yellow dots, Short vellus hairsAbstract
Objective To evaluate the therapeutic response of Excimer Laser in treatment of alopecia areata by dermoscopy.
Methods A total 34 patches in 24 patients were administered with 308nm excimer laser twice a week for 12 weeks and followed up after 3 months of last sitting. Treatment response was evaluated using regrowth scale (RGS) and dermoscope was used to assess disease activity, response to treatment and side effects.
Results Among 34 patches, 4 patches (13%) showed excellent response, 16 patches (47%) showed good response, 7 patches (20%) showed moderate response and 7 patches (20%) showed poor response. Dermoscopically, 27 patches (responders) showed reduction in black dots, yellow dots, broken hairs, tapering hairs and appearance of short vellus hairs which are signs of remitting disease, compared to 7 patches (nonresponders), who showed no change. Yellow dot was the most common dermoscopic finding seen among 85.3% at baseline.
Conclusion The excimer laser is one among the efficacious treatment for Alopecia areata. Dermoscopy is useful to assess the response to treatment and side effects.
References
1. Waśkiel‐Burnat A, Rakowska A, Sikora M, Olszewska M, Rudnicka L. Alopecia areata predictive score: A new trichoscopy‐based tool to predict treatment outcome in patients with patchy alopecia areata. J Cosmet Dermatol. 2020;19(3):746-51.
2. Ganjoo S, Thappa DM. Dermoscopic evaluation of therapeutic response to an intralesional corticosteroid in the treatment of alopecia areata. Indian J Dermatol Venereol Leprol. 2013;79:408-17.
3. Seetharam KA. Alopecia areata: An update. Indian J Dermatol Venereol Leprol. 2013;79:563-75.
4. Byun JW, Moon JH, Bang CY, Shin J, Choi GS. Effectiveness of 308-nm excimer laser therapy in treating alopecia areata, determined by examining the treated sides of selected alopecic patches. Dermatology. 2015;231(1):70-6.
5. Elnagar, Ali RA, Nada DW, Hassan AM, Hegab DS. Evaluation of the Efficacy of Excimer Light 308 nm Wavelength Versus Low level Laser in Treatment of Alopecia Areata. J Adv Med Res. 2021;33(18):120-9.
6. Zonunsanga. Comparative study of efficacy of excimer light therapy vs. intralesional triamcinolone vs. topical 5% minoxidil: an observational study. Our Dermatol Online. 2015;6(1):12-5.
7. Ohtsuki A, Hasegawa T, Komiyama E, Takagi A, Kawasaki J, Ikeda S. 308-nm excimer lamp for the treatment of alopecia areata: Clinical trial on 16 cases. Indian J Dermatol. 2013;58:32-6.
8. Al Hamzawi NK. Evaluation of the efficacy and safety of 308 nm monochromatic excimer lamp in the treatment of resistant alopecia areata. Int J Trichol. 2019;11:199-206.
9. Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: A multifactorial autoimmune condition. J Autoimmun. 2019;98:74-85.
10. Kranseler JS, Sidbury R. Alopecia areata: Update on management. Indian J Pediatr Dermatol. 2017;18:261-6.
11. Ghersetich I, Campanile G, Loti T. Alopecia areata: Immunohistochemistry and ultrastructure of infiltrate and identification of adhesion molecule receptors. Int J Dermatol. 1996;35:28-33.
12. Todes Taylor N, Turner R, Woods GS, Stratte PT, Morhenn VB. T cell subpopulations in alopecia areata. J Am Acad Dermatol. 1984;11:216-23.
13. Ito T. Immune checkpoint inhibitor associated alopecia areata. Br J Dermatol. 2017;176:1444-5.
14. Ramos PM, Anzai A, Duque-Estrada B, Melo DF, Sternberg F, Santos LDN, et al. Consensus on the treatment ofalopecia areata. An Bras Dermatol. 2020;95(S1):39-52.
15. Hegde SP, Naveen KN, Athanikar SB, Reshme P. Clinical and dermatoscopic patterns of alopecia areata: A tertiary care centre experience. Int J Trichol. 2013;5:132-6.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Deepadarshan Kalegowda, Shashikumar B Madegowda, Harish M Rajegowda, Meghana P Rathod
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
